Grifols (NASDAQ:GRFS) has been given an average rating of “Hold” by the nine analysts that are currently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $22.00.
Several brokerages have weighed in on GRFS. Zacks Investment Research cut Grifols from a “hold” rating to a “sell” rating in a report on Wednesday, May 9th. ValuEngine upgraded Grifols from a “hold” rating to a “buy” rating in a report on Friday, February 2nd. BidaskClub upgraded Grifols from a “sell” rating to a “hold” rating in a report on Tuesday, May 15th. Finally, Morgan Stanley lowered their target price on Grifols from $23.00 to $22.00 and set an “underweight” rating for the company in a report on Thursday, March 1st.
Grifols stock traded up $0.14 during mid-day trading on Tuesday, hitting $22.61. The company’s stock had a trading volume of 428,325 shares, compared to its average volume of 854,155. The company has a market capitalization of $15.44 billion, a PE ratio of 20.55, a price-to-earnings-growth ratio of 1.45 and a beta of 1.19. The company has a quick ratio of 1.35, a current ratio of 3.01 and a debt-to-equity ratio of 1.62. Grifols has a one year low of $19.92 and a one year high of $25.18.
Grifols (NASDAQ:GRFS) last issued its earnings results on Wednesday, February 28th. The biotechnology company reported $0.28 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.31 by ($0.03). Grifols had a return on equity of 18.53% and a net margin of 15.46%. The firm had revenue of $1.26 billion during the quarter, compared to analysts’ expectations of $1.29 billion. research analysts anticipate that Grifols will post 1.32 earnings per share for the current year.
Several hedge funds have recently modified their holdings of GRFS. Lenox Wealth Management Inc. lifted its holdings in shares of Grifols by 93.2% in the 4th quarter. Lenox Wealth Management Inc. now owns 11,460 shares of the biotechnology company’s stock worth $263,000 after buying an additional 5,529 shares during the period. Vaughan Nelson Investment Management L.P. lifted its stake in shares of Grifols by 2.6% during the 4th quarter. Vaughan Nelson Investment Management L.P. now owns 2,901,936 shares of the biotechnology company’s stock worth $66,513,000 after purchasing an additional 72,375 shares during the last quarter. Engadine Partners LLP purchased a new stake in shares of Grifols during the 4th quarter worth $39,350,000. Dean Capital Investments Management LLC purchased a new stake in shares of Grifols during the 4th quarter worth $214,000. Finally, Kornitzer Capital Management Inc. KS lifted its stake in shares of Grifols by 112.3% during the 4th quarter. Kornitzer Capital Management Inc. KS now owns 122,900 shares of the biotechnology company’s stock worth $2,817,000 after purchasing an additional 65,000 shares during the last quarter. Institutional investors and hedge funds own 22.22% of the company’s stock.
Grifols Company Profile
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others.
Receive News & Ratings for Grifols Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols and related companies with MarketBeat.com's FREE daily email newsletter.